A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Status:
COMPLETED
Trial end date:
2025-04-22
Target enrollment:
Participant gender:
Summary
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
The primary and secondary objectives of this study are to evaluate the safety, treatment effect, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.